Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica A Hellyer

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Translational Lung Cancer Research|September 27, 2019
Sex disparities in lung cancer incidence: validation of a long-observed trendJessica A Hellyer, Manali I Patel
Thoracic Surgery Clinics|April 25, 2020
Adjuvant ChemotherapyJessica A Hellyer, Heather A Wakelee
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and MesotheliomaChristine L Hann, Arnaud Scherpereel, Jessica A Hellyer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 11, 2020
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLCJessica A Hellyer, Sukhmani K Padda, Maximilian Diehn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2021
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLCJacqueline V Aredo, Jessica A Hellyer, Joel W Neal, et al.
Case Reports in Oncological Medicine|April 9, 2026
Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted TherapiesJessica Y Bae, Xiang Yu Gao, Josephine K Dermawan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2020
Everolimus in the treatment of metastatic thymic epithelial tumorsJessica A Hellyer, Madhu M Ouseph, Sukhmani K Padda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2021
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLCJessica A Hellyer, Jacqueline V Aredo, Millie Das, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancerJessica A Hellyer, Henning Stehr, Millie Das, et al.
Clinical Lung Cancer|November 28, 2021
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung CancerJessica A Hellyer, Maya N White, Rebecca M Gardner, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Translational Lung Cancer Research|September 27, 2019
Sex disparities in lung cancer incidence: validation of a long-observed trendJessica A Hellyer, Manali I Patel
Thoracic Surgery Clinics|April 25, 2020
Adjuvant ChemotherapyJessica A Hellyer, Heather A Wakelee
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and MesotheliomaChristine L Hann, Arnaud Scherpereel, Jessica A Hellyer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 11, 2020
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLCJessica A Hellyer, Sukhmani K Padda, Maximilian Diehn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2021
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLCJacqueline V Aredo, Jessica A Hellyer, Joel W Neal, et al.
Case Reports in Oncological Medicine|April 9, 2026
Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted TherapiesJessica Y Bae, Xiang Yu Gao, Josephine K Dermawan, et al.
Lung Cancer (Amsterdam, Netherlands)|October 2, 2020
Everolimus in the treatment of metastatic thymic epithelial tumorsJessica A Hellyer, Madhu M Ouseph, Sukhmani K Padda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2021
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLCJessica A Hellyer, Jacqueline V Aredo, Millie Das, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancerJessica A Hellyer, Henning Stehr, Millie Das, et al.
Clinical Lung Cancer|November 28, 2021
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung CancerJessica A Hellyer, Maya N White, Rebecca M Gardner, et al.
Pageof 2